[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610758":3},{"organization":4,"outcomesModule":7,"designInfo":27,"detailedDescription":11,"studyPopulation":11,"armGroups":36,"interventions":48,"overallOfficials":11,"centralContacts":57,"locations":63,"responsibleParty":81,"collaborators":11,"id":83,"slug":11,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":11,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":90,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":11,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":11,"overallStatus":102,"whyStopped":11,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"Stelexis BioSciences","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Incidence and severity of AEs, graded according to the NCI CTCAE Version 6.0",null,"56 days",[14,17,19,21,23,25],{"measure":15,"description":11,"timeFrame":16},"Pharmacokinetics of STLX-2012: area under the plasma concentration-time curve (AUC)","Day 1 - 29",{"measure":18,"description":11,"timeFrame":16},"Pharmacokinetics of STLX-2012: maximum observed serum concentration (Cmax)",{"measure":20,"description":11,"timeFrame":16},"Pharmacokinetics of STLX-2012: time corresponding to the occurrence of Cmax (Tmax)",{"measure":22,"description":11,"timeFrame":16},"Pharmacokinetics of STLX-2012: apparent terminal elimination half-life (t½)",{"measure":24,"description":11,"timeFrame":16},"Pharmacokinetics of STLX-2012: Clearance (CL)",{"measure":26,"description":11,"timeFrame":16},"Pharmacokinetics of STLX-2012: Volume of distribution (Vd)",{"allocation":28,"interventionModel":29,"interventionModelDescription":11,"primaryPurpose":30,"observationalModel":11,"timePerspective":11,"maskingInfo":31},"RANDOMIZED","PARALLEL","BASIC_SCIENCE",{"masking":32,"maskingDescription":11,"whoMasked":33},"DOUBLE",[34,35],"PARTICIPANT","INVESTIGATOR",[37,43],{"label":38,"type":39,"description":40,"interventionNames":41},"STLX-2012","EXPERIMENTAL","Single ascending doses of STLX-2012",[42],"Drug: STLX-2012",{"label":44,"type":45,"description":44,"interventionNames":46},"Placebo","PLACEBO_COMPARATOR",[47],"Other: Placebo",[49,53],{"type":50,"name":38,"description":51,"armGroupLabels":52,"otherNames":11},"DRUG","STLX-2012 IV",[38],{"type":54,"name":44,"description":55,"armGroupLabels":56,"otherNames":11},"OTHER","Placebo arm",[44],[58],{"name":59,"role":60,"phone":61,"phoneExt":11,"email":62},"Clinical Trials Office","CONTACT","508-543-6979","clinicaltrials@stelexis.com",[64],{"facility":65,"status":11,"city":66,"state":67,"zip":68,"country":69,"countryCode":70,"cosmosGeoPoint":71,"geoPoint":76,"contacts":77},"Nucleus Network Brisbane","Brisbane","Queensland","4006","Australia","AU",{"type":72,"coordinates":73},"Point",[74,75],153.02809,-27.46794,{"lat":75,"lon":74},[78],{"name":65,"role":60,"phone":79,"phoneExt":11,"email":80},"1800 243 733","brisbane@nucleusnetwork.com",{"type":82,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100610758",false,"NCT07231744","Study of STLX-2012 in Healthy Volunteers","A Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of STLX-2012 in Healthy Volunteers","Inclusion Criteria:\n\n* Male or female participants aged 18-55 years old, inclusive, at Screening.\n* Body mass index of 18-32 kg\u002Fm\\^2, inclusive\n* Healthy as determined by the investigator\n* Adequate hepatic and renal function\n* Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures\n* Male participants and females of childbearing potential must agree to use an effective method of contraception for 30 days after the last dose of STLX-2012\n\nExclusion Criteria:\n\n* Pregnant or lactating female.\n* Positive urine drug screen or alcohol breath test\n* Neutropenia, defined as neutrophil count \\\u003C2.0 x 10\\^9\u002FL\n* History of allergic reaction requiring treatment or anaphylactic reactions to any therapeutic drug.\n* Previous treatment with an IL-1RAP monoclonal antibody\n* History of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, inflammatory, or allergic disease (excluding mild seasonal allergies)",true,"ALL","18 Years","55 Years",{"count":94,"type":95},32,"ESTIMATED","INTERVENTIONAL",[98],"PHASE1","The purpose of this research is to establish the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single IV dose of STLX-2012.",[101],"Healthy Participants","NOT_YET_RECRUITING","2026-04-21",{"date":105,"type":106},"2026-04-22","ACTUAL",{"date":108,"type":95},"2026-10",{"date":110,"type":95},"2027-02",{"name":5,"class":6},1]